A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/519 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2550298
The use of tetrahydrofolate, methylene-tetrahydrofolate and/or methyl- tetrahydrofolate, and at least one multi-targeting antifolate, for the manufacture of a pharmaceutical composition for the treatment of cancer is disclosed. By combining the multi-targeting anti-folate with tetrahydrofolate, methylene-tetrahydrofolate and/or methyl-tetrahydrofolate, it is possible to remarkably reduce toxic side-effects without diminishing the anti-tumour action of the drugs. A pharmaceutical composition, a kit comprising the pharmaceutical composition as well as a method for the treatment of cancer are also disclosed.
Cette invention porte sur l'utilisation de tétrahydrofolate, de méthylène-tétrahydrofolate et/ou de méthyl-tétrahydrofolate et d'au moins un antifolique multicible pour fabriquer une composition pharmaceutique servant au traitement du cancer. Le fait de combiner l'antifolique multicible au tétrahydrofolate, au méthylène-tétrahydrofolate et/ou au méthyl-tétrahydrofolate permet de réduire considérablement les effets secondaires toxiques sans diminuer l'action anti-tumurale des médicaments. Cette invention concerne également une composition pharmaceutique, une trousse renfermant la composition pharmaceutique ainsi qu'une méthode de traitement du cancer.
Carlsson Goran
Gustavsson Bengt
Biofol Ab
Fetherstonhaugh & Co.
Isofol Medical Ab
LandOfFree
Reduction of toxicity of multi-targeting antifolates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of toxicity of multi-targeting antifolates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of toxicity of multi-targeting antifolates will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1379972